Hims & Hers Health Shares Rise on FDA Review of Compounded Peptide Therapies
Hims & Hers Health (HIMS) shares surged 11.12% on April 16, 2026, following the FDA's decision to review compounded peptide therapies. The move comes after the FDA may remove 12 peptides from its Category 2 restrictions, potentially allowing companies like HIMS to offer these therapies. The stock's rise was accompanied by broader market gains, with the S&P 500 and Nasdaq Composite both rising.
Topics: FDA regulations Hims & Hers Health peptide therapies stock performance telehealth